Optimised and validated for expression
BASE has established the specialised capabilities to develop mRNA medicines. We can design, manufacture and test mRNAs for a wide range of clinical applications.
Below, we describe each step in the pre-clinical development of an mRNA.
Good results begin with a good design. We have experience designing hundreds of mRNA for many applications.
Our software, mRNArchitect, can optimize the primary sequence for translation, stability, and immunogenicity.We also offer a useful catalog of validated RNA elements (UTRs, signal peptides etc).
We use nested PCR to rapidly produce an accurate DNA template. This method is accurate, reliably adds a full-length polyA tail, and is cell-free to avoid contaminants.
Watch our webinar to see Dr Seth Cheetham, in partnership with IDT, show rapid PCR amplification of DNA templates.
We produce high-quality mRNA, that is intact and free from double-stranded mRNA.
We can produce mRNA at different scales, from 100ug to 1 gram, and have experience with co-transcriptional and enzymatic 5’capping and polyadenylation methods.
All batches are supported by detailed analysis to ensure mRNA quality, integrity, and purity.
We can formulate mRNA in lipid nanoparticles (LNPs) for delivery.
We provide high-quality formulation services that are supported by quality control analysis of particle characteristics. Adjacent UQ research services can image and validate tissue delivery and biodistribution.
We can progress mRNA candidates to clinical stages.
This includes in vitro screening of multiple candidates to identify best-performing mRNAs. Our in vivo studies can analyse dosage, immune response, biodistribution and toxicity of mRNA-LNPs.
Our support team is available to help with your mRNA projects.
Research Laboratories
Level 3, AIBN (#75)
The University of Queensland
St Lucia, QLD 4072
Manufacture Facility
Level 6, Translational Research Institute
37 Kent St
Woolloongabba, QLD 4102